"Retatrutide FDA Approval Timeline & Status 2025-2027." November 2025.
In a large Swedish study published in JAMA Psychiatry in November 2024, scientists found that people who were taking the GLP-1 drugs semaglutide or liraglutide were less likely to be hospitalized for AUD
External resources New England Journal of Medicine: Retatrutide Phase 2 Trial for Obesity PMC: Comparative Efficacy of Tirzepatide vs Retatrutide Network Meta-Analysis Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease U.S
Examples of insurance plans that cover weight loss medication We found several insurance plans that cover weight loss and obesity medications: The Blue Cross Blue Shield Federal Employee Program covers name-brand Wegovy, Saxenda, Contrave, Xenical, Qsymia, and Lomaira, and generic benzphetamine, diethylpropion, orlistat, phendimetrazine, and phentermine
[5] [6] Any use in the UK would therefore involve an imported unlicensed medicine, with full clinical and legal responsibility resting with the prescriber
After that date, sterility and potency cannot be guaranteed
